Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Goldilocks Therapeutics logo — company profile

Goldilocks Therapeutics

Founded 2018 Seed Health Care, Health and Wellness

General Information

Company Name Goldilocks Therapeutics
Founded Year 2018
Founders / Decision Makers
Team member Team member
Industries Health Care, Health and Wellness
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with Goldilocks Therapeutics. To contact Goldilocks Therapeutics, visit goldilockstherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Goldilocks Therapeutics

Goldilocks Therapeutics is a promising player in the health care industry, specializing in preventive treatments for acute kidney injury, polycystic kidney disease, and other kidney conditions. The company, founded in 2018 and based in Bedford, New York, stands out for its use of proprietary mesoscale nanoparticles (MNPs) to precisely deliver therapeutic payloads to the renal tubule epithelium. The company's commitment to addressing critical medical needs has not gone unnoticed, as evidenced by its recent achievement of securing a Seed Round investment in January 2020. Notably, this round of funding was provided by the Accelerate NY Seed Fund, a move that reflects the industry's recognition of Goldilocks Therapeutics' potential in revolutionizing kidney disease treatment. Goldilocks Therapeutics' innovative approach to kidney disease treatment and its ability to attract support from established investors position it favorably within the competitive health care startup landscape. As the company continues to advance its groundbreaking technologies and strengthen its market presence, it is poised to make a significant impact on the field of kidney disease treatment and the broader health care industry.

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed 1
Accelerate NY Seed Fund
Accelerate NY Seed Fund
01 Jan 2020

Goldilocks Therapeutics Alternatives & Competitors

Goldilocks Therapeutics vs
Promedior
Promedior

Pioneering advanced therapies to heal fibrotic and inflammatory diseases at their source, enhancing...

Venture round
Biopharma, Biotechnology

FAQ About Goldilocks Therapeutics

Goldilocks Therapeutics focuses on creating preventive treatments for acute kidney injury, polycystic kidney disease, and various other kidney conditions. The company employs its proprietary mesoscale nanoparticles (MNPs) to precisely deliver therapeutic payloads to the renal tubule epithelium. Fou...
Goldilocks Therapeutics was founded in 2018.
Goldilocks Therapeutics operates in Health Care and Health and Wellness.
Goldilocks Therapeutics has completed 1 funding round. The latest funding stage is Seed.
Top alternatives and competitors to Goldilocks Therapeutics include Promedior. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Goldilocks Therapeutics and Promedior are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Goldilocks Therapeutics, https://bouncewatch.com/company/goldilocks-therapeutics, updated 28 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes